The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 5.00 (3.33%)
Spread: 10.00 (6.667%)
Open: 150.00
High: 155.00
Low: 155.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 May 2018 16:51

RNS Number : 8760N
Faron Pharmaceuticals Oy
11 May 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Timo Syrjälä

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

9.5.2018

6. Date on which issuer notified (DD/MM/YYYY):

11.5.2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.48%

4.48%

31,027,894

Position of previous notification (if

applicable)

3.18%

3.18%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

FI4000153309

550,830

840.000

1.78%

2.71%

SUBTOTAL 8. A

1,390.830

4.48%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Timo Syrjälä (Direct)

1.78%

1.78%

Acme Investments SPF Sarl (Indirect)

2.71%

2.71%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Lausanne

Date of completion

11/05/2018

 

 

.

Notes

 

i Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGMKKMGGRZM
Date   Source Headline
19th Jul 20237:01 amRNSFaron to Hold BEXMAB Study Conference Call
19th Jul 20237:00 amRNSBEXMAB study update
30th Jun 20234:52 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSAnnouncement of Placing
12th Jun 20237:00 amRNSExercise of options
9th Jun 20238:00 amRNSNew biomarker data from BEXMAB study at EHA2023
5th Jun 20237:00 amRNSBoard Member to Assume Transactional Advisor Role
24th Apr 20237:00 amRNSBexmarilimab Efficacy and Safety in MATINS Trial
19th Apr 20237:00 amRNSBexmarilimab KOL Event
18th Apr 20237:00 amRNSPoster Presentations at AACR 2023
17th Apr 20237:00 amRNSBEXMAB study update
13th Apr 20234:30 pmRNSFaron at Canaccord Oncology Virtual Conference
29th Mar 20237:00 amRNSAppointment of Chief Financial Officer
24th Mar 20231:35 pmRNSBoard Change
24th Mar 20231:30 pmRNSResults of AGM
22nd Mar 20237:00 amRNSPositive FDA Feedback to Progress Bexmarilimab
3rd Mar 20239:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
3rd Mar 20237:15 amRNSFaron´s Annual Report 2022 Published
3rd Mar 20237:00 amRNSFinancial Statement January 1 to December 31 2022
6th Feb 20236:00 pmRNSUpdate to Faron’s Financial Calendar for 2023
6th Feb 20237:00 amRNSNotice of 2022 Full-Year Results and Annual Report
1st Feb 20233:45 pmRNSHolding(s) in Company
27th Jan 20235:45 pmRNSHolding(s) in Company
27th Jan 20237:00 amRNSResults of Placing
26th Jan 20234:30 pmRNSProposed Issue and Placing
16th Jan 202311:00 amRNSPrice Monitoring Extension
16th Jan 20239:05 amRNSSecond Price Monitoring Extn
16th Jan 20239:00 amRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSTitle: BEXMAB study update
23rd Dec 20227:00 amRNSFaron’s Financial Calendar for 2023
5th Dec 20227:00 amRNSBEXMAB Study Update
1st Dec 20227:00 amRNSFaron Appoints Maija Hollmén PhD as CSO
18th Nov 20224:30 pmRNSAmendment Terms and Conditions with IPF Partners
2nd Nov 20227:00 amRNSFaron Announces Poster Presentation at SITC
31st Oct 20227:00 amRNSBEXMAB Study Update
19th Oct 20229:20 amRNSHolding(s) in Company
18th Oct 202212:30 pmRNSHolding(s) in Company
18th Oct 20227:00 amRNSFaron Announces Melanoma Cohort Data from MATINS
14th Oct 20227:00 amRNSResults of Placing
13th Oct 20225:31 pmRNSProposed Issue and Placing of Shares
22nd Sep 20227:00 amRNSGrant of Options
20th Sep 20227:00 amRNSTop-Line Data on Bexmarilimab Dose Variation
14th Sep 20227:00 amRNSFaron to Host Bexmarilimab Update Webcast
13th Sep 20227:00 amRNSTraumakine Data Presented at MHSR Symposium
7th Sep 20221:00 pmRNSFaron to Present at Upcoming Conferences
25th Aug 20227:00 amRNSFaron Reports 2022 Half-Year Financial Results
8th Aug 20227:00 amRNSNotice of Half-Year Financial Results
7th Jul 20229:45 amRNSResults of EGM
30th Jun 20225:00 pmRNSHolding(s) in Company
28th Jun 20221:47 pmRNSRegistration of New Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.